Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Plant-derived extracellular vesicles as tools and targets for inflammatory diseases

Tan F., Liu W., Li T., Li L., Chen Z., Thakur A.

Narrative Review on Chronic Inflammation, published in J Nanobiotechnology (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Nanobiotechnology (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41864926
PMCID
PMC13126889
DOI
10.1186/s12951-026-04294-5
Citations
4

Abstract (original English)

Inflammatory diseases remain a major clinical challenge due to their complex pathologies and the limitations of current anti-inflammatory therapies. Conventional treatments, such as non-steroidal anti-inflammatory drugs and biologics, often provide incomplete relief and cause significant side effects, creating an urgent need for safer, more effective interventions. Plant-derived extracellular vesicles (PDEVs)-natural nanocarriers with inherent biocompatibility and cross-kingdom regulatory capacity-have emerged as a novel therapeutic approach that could address these shortcomings by safely delivering anti-inflammatory signals across species boundaries. This review examines PDEVs as both therapeutic tools and targets in inflammatory diseases, delineating their unique properties, anti-inflammatory mechanisms, and translational potential. Key topics include the biogenesis, composition, and isolation of PDEVs; their multifaceted roles in modulating immune responses; and evidence of efficacy in various models of inflammatory disease. Collectively, current findings indicate that PDEVs represent biocompatible, multi-target agents that effectively attenuate inflammation and promote tissue repair by overcoming the barriers to drug delivery and toxicity limitations of conventional therapies. Ongoing advances in omics technologies and bioengineering are expected to advance the characteriza

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansPlantsInflammationAnti-Inflammatory AgentsDrug Delivery SystemsExtracellular Vesicles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research